[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100561594":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":10,"locations":18,"responsibleParty":37,"collaborators":10,"id":39,"slug":40,"hasResults":41,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":10,"eligibilityCriteria":45,"healthyVolunteers":41,"sex":46,"minAge":47,"maxAge":48,"enrollmentInfo":49,"targetDuration":10,"studyType":52,"phases":10,"briefSummary":53,"conditions":54,"keywords":10,"overallStatus":20,"whyStopped":10,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":65},{"fullName":5,"class":6},"Shanghai Yueyang Integrated Medicine Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Cross-sectional study and retrospective cohort study",null,"This research was conducted in two phases. Initially, a cross-sectional study was performed to assess the correlation between statin usage prior to hospital admission and the initial state of liver enzymes among patients. Subsequently, a retrospective cohort study was undertaken, wherein patients who had not been on statins prior to admission were categorized into two groups based on their statin usage post-admission.",[13],"Other: stain",[15],{"type":6,"name":16,"description":11,"armGroupLabels":17,"otherNames":10},"stain",[9],[19],{"facility":5,"status":20,"city":21,"state":22,"zip":10,"country":23,"countryCode":24,"cosmosGeoPoint":25,"geoPoint":30,"contacts":31},"RECRUITING","Shanghai","Shanghai Municipality","China","CN",{"type":26,"coordinates":27},"Point",[28,29],121.45806,31.22222,{"lat":29,"lon":28},[32],{"name":33,"role":34,"phone":35,"phoneExt":10,"email":36},"Jia Zhou","CONTACT","+86 21-6516-1782","807121843@qq.com",{"type":38,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100561594","hepatic-safety-of-statin-use-in-neurology-inpatients-100561594",false,"NCT06592196","Hepatic Safety of Statin Use in Neurology Inpatients","A Retrospective Study on the Hepatic Safety of Statin Use in Neurology Inpatients","Inclusion Criteria:\n\n1. Patients hospitalized in the Department of Neurology of Yueyang Hospital from June 2020 to February 2023.\n2. Age ≥18 and ≤85 years old, both sexes.\n3. Meet the diagnostic criteria of cerebrovascular disease (L1-8B0), headache disease (L1-8A8) and dizziness and vertigo (MB48) in ICD-11.\n\nExclusion Criteria:\n\n1. Incomplete medical history.\n2. 1 days ≤ patients with \\\u003C 7 days of prior statin use.\n3. Patients with malignant tumors (ICD-11 code L1-2A0, L1-2A2, L1-2B5, L1-2E6 diseases) and hematological diseases (ICD-11 code L1-3A0, L1-3B1, L1-3B8 diseases).","ALL","18 Years","85 Years",{"count":50,"type":51},2000,"ESTIMATED","OBSERVATIONAL","This research employs a cross-sectional study and a retrospective cohort study to analyze the liver safety of statin use among inpatients in the neurology department in China from different perspectives. The aim is to supplement evidence-based medicine and provide guidance for the clinical use of statins.",[55],"Statin Adverse Reaction","2024-09-11",{"date":58,"type":59},"2024-09-19","ACTUAL",{"date":61,"type":59},"2024-08-10",{"date":63,"type":51},"2024-12-10",{"name":5,"class":6},1]